Oxford Nanopore Technologies Revenue and Competitors
Estimated Revenue & Valuation
- Oxford Nanopore Technologies's estimated annual revenue is currently $334.6M per year.
- Oxford Nanopore Technologies's estimated revenue per employee is $248,000
- Oxford Nanopore Technologies's current valuation is $1.6B.
Employee Data
- Oxford Nanopore Technologies has 1349 Employees.
- Oxford Nanopore Technologies grew their employee count by 11% last year.
Oxford Nanopore Technologies Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4280M | 9130 | -4% | $28M | $63.3B |
#2 | $49.1M | 269 | 3% | N/A | N/A |
What Is Oxford Nanopore Technologies?
Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis. Our technology and commercial model has already opened up DNA analysis to researchers who previously had no direct access to sequencing technologies, freeing them up to perform analyses in their own labs, in real time or in the field. Over time, the technology will continue to improve, new form factors of the technology will be introduced and workflows will be further simplified by new preparation techniques or analysis workflows. This technology pathway is designed to enable the analysis of any living thing, by any person, in any environment. Oxford Nanopore has developed the worlds first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology. Commercially available since 2015, the MinION is in use by a thriving community of scientists in >50 countries, where it is enabling myriad applications within the traditional laboratory environment and in the field. Nanopore sensing technology is fully scalable. The GridION X5 is a desktop device that includes compute module and the ability to run up to five MinION Flow Cells. The the high-throughput/sample number PromethION is currently being released in the PromethION Early Access Programme (PEAP). Oxford Nanopore is focused on making DNA based analyses easy enough for any user and so we are working to simplify the sample preparation and data analysis processes. For sample preparation this includes a 5-10 minute sample prep kit, and VolTRAX (in development), a rapid, programmable, portable, disposable sample preparation device designed to prepare DNA for addition to a nanopore sequencing device.
keywords:Agriculture,Biotechnology,Healthcare,Medical Diagnostics,PharmaceuticalsN/A
Total Funding
1349
Number of Employees
$334.6M
Revenue (est)
11%
Employee Growth %
$1.6B
Valuation
N/A
Accelerator
Oxford Nanopore Technologies's People
Name | Title | Email/Phone |
---|---|---|
1 | Director Distribution & LATAM | Reveal Email/Phone |
2 | Director, Sales Training, Americas | Reveal Email/Phone |
3 | Director, Technical Services (Production Scale Sequencing) | Reveal Email/Phone |
4 | Director Inside Sales - Americas | Reveal Email/Phone |
5 | Senior Technical Applications Specialist | Reveal Email/Phone |
6 | Clinical Bioinformatics Lead, Associate Director | Reveal Email/Phone |
7 | Director Clinical Segment Marketing | Reveal Email/Phone |
8 | Nanopore Account Executive | Reveal Email/Phone |
9 | Account Executive | Reveal Email/Phone |
10 | Commercial Marketing Manager | Reveal Email/Phone |
Oxford Nanopore Technologies News
Oxford Nanopore Technologies Limited develops and commercializes a technology platform using nanopore-based sensing for the analysis of various...
Oxford Nanopore's technology sequences DNA or RNA molecules of any length, from short to ultra-long. It is the only technology on the market...
NEW YORK - Oxford Nanopore Technologies (ONT) announced on Friday that it has reached "an amicable resolution" with the UK Department of...
By Jaime Llinares Taboada Oxford Nanopore Technologies Ltd. said Thursday that it intends to raise around 300 million pounds ($415.3 million) at its initial public offering in London, half of which will be provided by Texas-based software provider Oracle Corp. The DNA-sequencing specialist, wh ...
By Jaime Llinares Taboada Oxford Nanopore Technologies Ltd. said Thursday that it intends to raise around 300 million pounds ($415.3 million) at its initial public offering in London, half of which will be provided by Texas-based software provider Oracle Corp. The DNA-sequencing specialist, wh ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1430M | 1495 | -1% | $80M |
#2 | $500.1M | 2081 | 4% | N/A |
#3 | $531.7M | 2110 | N/A | N/A |
#4 | $1083M | 2502 | 6% | N/A |
#5 | $300M | 3513 | 4% | N/A |
Oxford Nanopore Technologies Executives
Name | Title |
---|---|
Gordon Sanghera | Chief Executive Officer |
Spike Willcocks | CHIEF BD OFFICER |
Clive Brown | Chief Technology Officer |
Tim Cowper | CFO |
John M. | Chief Scientific Officer |
John Milton | Chief Scientific Officer |
Zoe McDougall | VP, CORPORATE AND COMMUNICATIONS |
Kristy Loomis - SPHR | Senior Vice President Product Management |
Bob Arsenault | VP and General Counsel |
Andy Davies | VP Global IT & Digital |
James Clarke | Vice President of Platform Technology |
Lakmal Jayasinghe | VP, R&D - Biologics |
Rhodri Davies | VP Operations |
Martyn Andrews | VP Intellectual Property |
Dan Turner | VP, Applications |
Sarah Lapworth MCIPD | VP, Global HR |
Richard Compton | Senior Vice President of Commercial Operations |
Anthony Jones | VP, Engineering at Oxford Nanopore Technologies Ltd |
Stuart Reid | VP Development |
Zoe McDougall | VP Marketing and Corporate Affairs |
Louisa Ludbrook | VP, Global Sales |
Nirmala Santiapillai | Vice President, Global Service |
Christopher Brown | Vice President, Strategic Programmes |
Rosemary Dokos | VP, Product & Programme Management |
Roger Pettett | VP, Informatics |
Emma Stanton | VP, Clinical |
Rhodri Davies | VP, Operations |
Chris Brown | VP, Strategic Programmes |
Kristen Stoops | VP, Business Development |
Howard Orman | VP, Tech Transfer, Quality & Regulatory |
John Schoellerman | SVP, Corporate Development and Investment |
Jordan Herman | VP, GENERAL COUNSEL |